AI Drug Development: FDA Releases Draft Guidance

FDA AI Draft Guidance – On January 6, 2025, the U.S. Food and Drug Administration (FDA) released a draft guidance titled “Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products.” This document outlines the types of information the FDA may require when evaluating the use of Artificial Intelligence (AI) in drug development. The guidance emphasizes establishing AI model credibility, especially in contexts that impact patient safety, drug quality, or clinical reliability.

This article simplifies the guidance and explains its critical components, including the risk framework, required disclosures, and opportunities for innovation. We’ll also discuss how these developments intersect with tools like Atlas Compliance, a platform aiding businesses in meeting FDA standards.

Defining the Question of Interest

The first step in the FDA’s framework involves identifying the question of interest that the AI model addresses. This could include:

• Selecting participants for clinical trials (e.g., inclusion and exclusion criteria).
• Classifying risks associated with trial participants.
• Analyzing clinical outcomes.
• Improving quality control in drug manufacturing processes.

By clearly defining this question, stakeholders can align their AI models with specific regulatory and operational goals.

Contexts of Use

The guidance introduces contexts of use, which define the scope and role of AI in addressing the identified question. Examples include:

1. Clinical trial design and management.
2. Evaluating patients during trials.
3. Analyzing clinical trial data.
4. Ensuring pharmaceutical manufacturing quality.
5. Utilizing digital health technologies in drug development.
6. Generating real-world evidence (RWE).
7. Monitoring drug life cycles.

These contexts determine the potential risks associated with the AI model and the level of credibility required.

Key Considerations:

• AI models with greater influence on decision-making require more robust evaluations.
• Human oversight in processes involving AI can reduce risks and disclosure burdens.

Risk Framework for Information Disclosure

The FDA’s framework evaluates risks based on:

1. Model Influence Risk: How significantly the AI model affects decision-making.
2. Decision Consequence Risk: The potential impact of those decisions, particularly on patient safety.

Disclosure Requirements:

• High-Risk Models: Comprehensive information about architecture, training data, validation methods, and performance metrics is required.
• Low-Risk Models: Less detailed information suffices.

For instance, AI models managing clinical trial participants’ safety are considered high-risk and must meet stringent transparency requirements. Conversely, models supporting non-clinical activities may have reduced disclosure demands.

Establishing AI Model Credibility

To establish credibility, the FDA recommends providing details on:

1. Model Description: Including architecture and algorithms.
2. Training Data: Addressing data sources, quality, and fitness for purpose.
3. Validation Processes: Demonstrating accuracy, reliability, and bias detection.
4. Life Cycle Maintenance: Ensuring model outputs remain credible as inputs or conditions change.

Intellectual Property (IP) Considerations

The guidance’s transparency requirements create challenges for maintaining trade secrets. Stakeholders are advised to:

• Patent AI Innovations: Protect architectures, training methods, and validation processes.
• Use Trade Secrets Strategically: For AI models unrelated to patient safety or drug quality, consider withholding proprietary details from public disclosures.

Opportunities for Innovation

The FDA’s rigorous requirements open doors for technological advancements, including:

• Explainable AI (XAI): Models that clarify decision-making processes.
• Bias Detection Systems: Tools for identifying and mitigating bias in training data.
• Automated Monitoring: Systems to track and validate AI performance over time.
• Real-World Data Integration: Methods to enhance AI models using diverse datasets.

FAQs

Q1: What is the FDA’s main concern with AI models in drug development?
The FDA is primarily concerned with ensuring that AI models used in drug development are credible, reliable, and safe, particularly when they influence patient safety or drug quality.

Q2: How does Atlas Compliance help with FDA requirements?
Atlas helps businesses stay FDA-compliant by providing detailed observation reports, and warning letters and offering actionable insights to prevent violations.

Q3: What are the key disclosure requirements for high-risk AI models?
High-risk AI models must disclose architecture details, training data sources, validation metrics, performance assessments, and life cycle maintenance plans.

Conclusion

The FDA’s draft guidance represents a significant step toward ensuring AI’s safe and effective integration into drug development. By focusing on context-specific risks and transparency, the guidance provides a clear pathway for compliance while fostering innovation. Businesses leveraging AI, such as those using tools like Atlas Compliance, have an opportunity to lead in this evolving landscape by prioritizing credibility, transparency, and innovation.